ABC Arbitrage SA Invests $2.24 Million in Zoetis Inc. $ZTS

ABC Arbitrage SA acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 14,387 shares of the company’s stock, valued at approximately $2,244,000.

A number of other institutional investors have also made changes to their positions in ZTS. Lindbrook Capital LLC raised its position in shares of Zoetis by 1.8% during the first quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after acquiring an additional 65 shares during the last quarter. Scott & Selber Inc. lifted its position in shares of Zoetis by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares during the period. Secure Asset Management LLC boosted its stake in Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after acquiring an additional 68 shares in the last quarter. Moment Partners LLC grew its holdings in Zoetis by 3.2% in the second quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC increased its stake in Zoetis by 6.7% in the second quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $120.09 on Wednesday. The firm has a market capitalization of $52.92 billion, a PE ratio of 20.67, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12 month low of $117.26 and a 12 month high of $181.85. The business’s 50-day moving average price is $142.82 and its 200-day moving average price is $152.16.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 earnings per share. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Argus reaffirmed a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Stifel Nicolaus set a $140.00 target price on shares of Zoetis in a report on Tuesday, November 4th. Finally, UBS Group dropped their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Zoetis has a consensus rating of “Moderate Buy” and an average price target of $182.50.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.